Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL16057457 | 0.89 | SLC1A2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL5510959 | 0.88 | CYP2C19 (0.48) | CYP2C19 | |
| SCHEMBL24743654 | 0.80 | — | — | |
| SCHEMBL4146679 | 0.76 | — | — | |
| SCHEMBL30879561 | 0.74 | CYP2C19 (0.58) | CYP2C19 | |
| Hydrochloric Acid SCHEMBL17476050 | 0.74 | CYP2C19 (0.37) | CYP2C19FFAR3 | |
| SCHEMBL18756259 | 0.73 | — | — | |
| SCHEMBL4149507 | 0.73 | ALDH1A1 (0.42) | CYP2C19FFAR3 | |
| SCHEMBL20988000 | 0.72 | CYP2C19 (0.32) | CYP2C19FFAR3 | |
| SCHEMBL245571 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998260-B1 | SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230295076-A1 | ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-11207323-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200316065-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3660013-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10639308-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190167679-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10183021-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-9586937-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586937-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160375022-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160347738-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160347738-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295076-A1 | ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF | CYP11B2, ALDH7A1, CYP11B1 | CYP2C19 80/4885FFAR3 2109/4885TP53 2996/4885 |
| US-11207323-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | CYP2C19 1024/4885FFAR3 2714/4885TP53 4691/4885 |
| US-10639308-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | CYP2C19 1024/4885FFAR3 2714/4885TP53 4691/4885 |
| US-20160347738-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | CYP2C19 1024/4885FFAR3 2714/4885TP53 4691/4885 |
| US-10183021-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | CYP2C19 1024/4885FFAR3 2714/4885TP53 4691/4885 |
| US-20160375022-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | CYP2C19 1024/4885FFAR3 2714/4885TP53 4691/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | CYP2C19 3029/4885FFAR3 4786/4885TP53 3964/4885 |
| US-20190167679-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | CYP2C19 1024/4885FFAR3 2714/4885TP53 4691/4885 |
| US-20160031903-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | CYP2C19 1024/4885FFAR3 2714/4885TP53 4691/4885 |
| US-20200316065-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | CYP2C19 1024/4885FFAR3 2714/4885TP53 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.